Product Description
Mechanisms of Action: EGFR Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck KGaA
Company Location: GERMANY HRB 6164 I8
Company CEO: Belen Garijo
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Colorectal Cancer|Gastrointestinal Cancer|Adenocarcinoma|Esophageal Cancer
Phase 1: Gastrointestinal Cancer|Adenocarcinoma|Esophageal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-000899-32 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2009-06-05 |
|
MATRIX EG | P2 |
Completed |
Esophageal Cancer|Gastrointestinal Cancer |
2008-07-31 |
|
MAURICE | P2 |
Completed |
Colorectal Cancer |
2007-10-30 |
|
EMD 72000-031 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2007-07-31 |